THRX Stock News 27.04 05/13/2014 19:15:25 Theravance (THRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Theravance (THRX) 27.04 $THRX

Theravance Has Returned 23.2% Since SmarTrend Recommendation (THRX)
Comtex SmarTrend(R) - Tue May 13, 10:08AM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on March 7th, 2014 at $34.65. In approximately 2 months, Theravance has returned 23.23% as of today's recent price of $26.60.

Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at:

This Week in Biotech: Chelsea Therapeutics Finds a Buyer While Corcept Implodes
Sean Williams, The Motley Fool - Motley Fool - Sat May 10, 11:15AM CDT
With the  SPDR S&P Biotech Index  up  20% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

Got Dividend? This Biotech Just Initiated a Nearly 4% Yield!
Sean Williams, The Motley Fool - Motley Fool - Sat May 10, 9:25AM CDT
Few industries offer investors as much long-term opportunity as the health-care sector. It's filled with tales of stocks doubling in a day on positive clinical data or the approval of a new medical device, as well as companies being chopped off at...

Theravance Study Results Confirm in vitro Potency of VIBATIV(R) (telavancin) and Efficacy in Patients With Complicated Skin and Skin Structure Infections Including MRSA
Marketwire - Fri May 09, 5:01PM CDT
Theravance, Inc. (NASDAQ: THRX) (the "Company" announced today new data from multiple studies of VIBATIV(R) (telavancin). These study results, which offer new insight into the product's in vitro potency, efficacy and safety, will be the focus of multiple presentations over the next several days at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain. Combined, the data presentations confirm the in vitro potency of VIBATIV(R) and its efficacy in patients with complicated skin and skin structure infections (cSSSI) including methicillin-resistant Staphylococcus aureus (MRSA).

European marketing authorisation granted for Anoro (umeclidinium/vilanterol) for the treatment of COPD
M2 - Fri May 09, 6:43AM CDT
Pharmaceutical companies GlaxoSmithKline plc (LSE/NYSE:GSK) and Theravance Inc (NASDAQ: THRX) announced on Thursday that marketing authorisation for Anoro (umeclidinium/vilanterol) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) has been granted by the European Commission.

Anoro(R) (Umeclidinium/Vilanterol) Gains Marketing Authorisation in Europe for the Treatment of COPD
Marketwire - Thu May 08, 10:12AM CDT
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Commission has granted marketing authorisation for Anoro(R) (umeclidinium/vilanterol) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Split Update Overshadows Wider Q1 Loss at Theravance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 10:40AM CDT
Theravance's (THRX) first quarter 2014 loss of 62 cents per share was wider than the Zacks Consensus Estimate of a loss of 53 cents per share.

Theravance, Inc. Announces May 15 Record Date and June 2 Share Issue Date for Separation Into Two Companies via a Stock Dividend
Marketwire - Wed May 07, 5:18AM CDT
Theravance, Inc. (NASDAQ: THRX) (the "Company" or "Theravance" has announced the record date of May 15, 2014 for the Company's strategic separation into two independent, publicly traded companies via a stock dividend. Each Theravance stockholder of record as of 5:00 p.m. Eastern Time on May 15, 2014 will receive shares of Theravance Biopharma, Inc. on the issue date, currently expected to be June 2, 2014. In addition, the Company announced that it intends to initiate a quarterly cash dividend to stockholders of Theravance of $0.25 per share beginning in the third quarter of 2014.

Theravance Unveils Separation Plans and Initiates Dividend As Q1 Loss Widens 81%
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 6:16PM CDT
Things are about to getting very exciting for existing shareholders of biopharmaceutical company Theravance , with the company announcing its first-quarter results after the closing bell and setting a record date of May 15 for its split into two...

Will These 3 Biotechs Bounce Back?
Dan Carroll, The Motley Fool - Motley Fool - Tue May 06, 5:30PM CDT
The biotech sector has been hit hard in 2014, with many of the biggest names in the industry taking falls. Three top companies,  Alnylam Pharmaceuticals , Theravance , and Amgen , are all down year to date. But are these tumbling biotech stocks...

Downtrend Call Working As Theravance Stock Falls 22.0% (THRX)
Comtex SmarTrend(R) - Tue May 06, 9:24AM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on March 7th, 2014 at $34.65. In approximately 2 months, Theravance has returned 21.96% as of today's recent price of $27.04.

This Week in Biotech: Merger Mania Continues
Sean Williams, The Motley Fool - Motley Fool - Sat May 03, 12:15PM CDT
With the  SPDR S&P Biotech Index  up  23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

Theravance to Present New Data Confirming in vitro Potency of VIBATIV(R) (telavancin) and Efficacy in Patients With Complicated Skin and Skin Structure Infections Including MRSA at 2014 ECCMID Conference
Marketwire - Thu May 01, 7:04AM CDT
Theravance, Inc. (NASDAQ: THRX) (the "Company" announced today that data from multiple studies of VIBATIV(R) (telavancin), the Company's FDA-approved antibiotic, will be presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain, on May 10 - 13, 2014. New and retrospectively analyzed data on the product's in vitro potency, efficacy and safety will be discussed as part of one oral and three poster presentations. The presented findings highlight the role of VIBATIV(R) as an effective alternative treatment for resolving susceptible serious Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA).

Product Launches, Conference Call Schedules, Promotions, and Appointments - Analyst Notes on Theravance, Volcano, Steris, Cyberonics and Kythera
PR Newswire - Thu May 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Theravance Inc. (NASDAQ: THRX), Volcano Corporation (NASDAQ: VOLC), Steris Corp. (NYSE: STE), Cyberonics Inc. (NASDAQ: CYBX) and Kythera Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1881-100free.

Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia
Marketwire - Wed Apr 30, 3:09PM CDT
Theravance, Inc. (NASDAQ: THRX) today announced positive results from a Phase 2 study of TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor (NSRI), in patients with fibromyalgia (FM). The study demonstrated statistically significant and clinically meaningful improvements in the primary and secondary endpoints at the 20 mg dose of TD-9855 compared to placebo. The 5 mg dose did not meet statistical significance for the primary endpoint. Both doses were generally well tolerated.

Theravance to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Marketwire - Tue Apr 29, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014, at 10:00 a.m. PDT. The conference will be held from May 13-15, 2014 at the Encore at Wynn Las Vegas, Las Vegas, NV.

Could This Be the Next Health Care Acquisition Target?
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 11:05AM CDT
If you follow the health-care sector in any way, shape, or form, the pay week and a half has been  nothing short of incredible. Merger and acquisition activity usually comes in spurts, and true megadeals are rare . But in recent days we have been...

GlaxoSmithKline & Theravance partnership unveils Anoro Ellipta in the US for the treatment of COPD
M2 - Tue Apr 29, 5:44AM CDT
Healthcare company GlaxoSmithKline (LSE:GSK)(NYSE:GSK) and Theravance (NasdaqGS:THRX) Monday jointly reported the launch of Anoro Ellipta for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in retail pharmacies in the US.

Theravance Down 23.6% Since SmarTrend Downtrend Call (THRX)
Comtex SmarTrend(R) - Mon Apr 28, 5:11PM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on March 7th, 2014 at $34.65. In approximately 2 months, Theravance has returned 23.58% as of today's recent price of $26.48.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 64

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 96

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 48

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 222

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 104

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 98

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 98

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 136

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 30

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 126

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Scaling New Heights: S&P 500's Path to 6,500

Updated Category News Views 260

Market Rally Highlights The financial markets witnessed an impressive surge recently, with significant recoveries noted in leading indexes. The S&P 500, a crucial gauge for large-cap stocks, notably rose by 10.6% during the second quarter of the year. Many factors contributed to this remarkable increase, underscoring investor confidence despite some ongoing challenges in...

Continue Reading
Pultruded Spar Cap Market Growth: Forecasting US$ 2.1 Billion

Updated Category News Views 194

Insights into the Pultruded Spar Cap Market and Future Growth The Pultruded Spar Cap Market is on the cusp of significant expansion, with projections suggesting a robust annual growth rate of 16.7% from 2024 through 2030. Industry analyses indicate that this favorable trend could lead to a market size of US$ 2.1 billion by the end of the projection period. This report is...

Continue Reading
Irritable Bowel Syndrome Treatment Growth Projections 2033

Updated Category News Views 107

Irritable Bowel Syndrome: An Overview Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that can significantly affect a person's quality of life, leading to a range of uncomfortable symptoms such as abdominal discomfort, bloating, and irregular bowel movements. With various subtypes like IBS with Diarrhea (IBS-D) and IBS with Constipation (IBS-C), it...

Continue Reading
Anoto Group Reports Second Quarter Results 2024

Updated Category News Views 242

Overview of the Interim Report for 2024 The interim report covering January to June 2024 provides important insights into Anoto Group AB's operations and financial health. Anoto Group continues to be a leader in technology, particularly in optical recognition and digital writing. This report emphasizes key financial metrics and the company's strategic initiatives in a...

Continue Reading
Mission Critical Group Welcomes Mark Feasel as VP of Sales

Updated Category News Views 276

Mission Critical Group Appoints New Vice President of Sales Mission Critical Group (MCG), a leader in critical power infrastructure solutions, is excited to announce the appointment of industry veteran Mark Feasel as the Vice President of Sales in the Commercial and Innovation Division. With this strategic addition, MCG aims to enhance its sales strategy and broaden its...

Continue Reading